Literature DB >> 24493023

Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer.

Kathrin Rupertus1,2, Janine Sinistra3, Claudia Scheuer3, Ruth M Nickels3, Martin K Schilling1,4, Michael D Menger3, Otto Kollmar5,6.   

Abstract

The chemokine CXCL12 has a decisive role in tumor progression by mediating pro-angiogenic and pro-metastatic effects through its receptor CXCR4. The CXCL12 pathway is connected with another chemokine, CXCL11, through its second receptor CXCR7. CXCL11 also binds to the CXCR3 receptor. CXCL11 function in tumor angiogenesis is likely receptor dependent because CXCR3 predominantly mediates angiostatic signals whereas CXCR7 mediated signaling is rather angiogenic. We therefore studied the interaction of CXCL12 and CXCL11 in an in vivo model of colorectal cancer metastasis. GFP-transfected CT26.WT colorectal cancer cells were implanted into the dorsal skinfold chamber of syngeneic BALB/c mice. The animals received either peritumoral application of CXCL11 or intraperitoneal injections with neutralizing antibodies against CXCL11, CXCL12 or both. Tumor growth characteristics, angiogenesis, cell migration, invasive tumor growth, tumor cell proliferation and apoptosis were studied by intravital fluorescence microscopy and immunohistochemistry during an observation period of 14 days. Local exposure to CXCL11 significantly stimulated tumor growth compared to controls and enhanced invasive growth characteristics without affecting tumor angiogenesis and tumor cell migration. Neither CXCL11 nor CXCL12-blockade had a significant impact on tumor growth and angiogenesis, whereas the combined neutralization of CXCL11 and CXCL12 almost completely abrogated tumor vessel formation. As a consequence, tumor growth and invasive growth characteristics were reduced compared to the other groups. The results of the present study underline the interaction of CXCL12 and CXCL11 during tumor angiogenesis. The combined blockade of both signaling pathways may provide an interesting anti-angiogenic approach for anti-tumor therapy.

Entities:  

Keywords:  Angiogenesis; CXCL11; CXCL12; Chemokines; Colorectal cancer; I-TAC; SDF-1

Mesh:

Substances:

Year:  2014        PMID: 24493023     DOI: 10.1007/s10585-014-9639-4

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  31 in total

1.  The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.

Authors:  Paul J Hensbergen; Pepijn G J T B Wijnands; Marco W J Schreurs; Rik J Scheper; Rein Willemze; Cornelis P Tensen
Journal:  J Immunother       Date:  2005 Jul-Aug       Impact factor: 4.456

2.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.

Authors:  Roderick J Phillips; Marie D Burdick; Marin Lutz; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  Am J Respir Crit Care Med       Date:  2003-03-05       Impact factor: 21.405

3.  Chemokine receptor CXCR7 mediates human endothelial progenitor cells survival, angiogenesis, but not proliferation.

Authors:  Xiaoqing Yan; Shaoxi Cai; Xin Xiong; Wei Sun; Xiaozhen Dai; Sijia Chen; Qunfang Ye; Zhen Song; Qifeng Jiang; Zhiling Xu
Journal:  J Cell Biochem       Date:  2012-04       Impact factor: 4.429

4.  Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells.

Authors:  Ke Zheng; Hong-Yuan Li; Xin-Liang Su; Xiao-Yi Wang; Tian Tian; Fan Li; Guo-Sheng Ren
Journal:  J Exp Clin Cancer Res       Date:  2010-04-11

5.  CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Authors:  Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-26       Impact factor: 11.205

6.  Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.

Authors:  Susan Costantini; Raffaele Raucci; Teresa De Vero; Giuseppe Castello; Giovanni Colonna
Journal:  Cytokine       Date:  2013-06-15       Impact factor: 3.861

Review 7.  Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.

Authors:  Anup Kumar Singh; Rakesh Kumar Arya; Arun Kumar Trivedi; Sabyasachi Sanyal; Rathindranath Baral; Olivier Dormond; David M Briscoe; Dipak Datta
Journal:  Cytokine Growth Factor Rev       Date:  2012-09-16       Impact factor: 7.638

8.  Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.

Authors:  Merav Darash-Yahana; Eli Pikarsky; Rinat Abramovitch; Evelyne Zeira; Boaz Pal; Rebekah Karplus; Katia Beider; Shani Avniel; Shafika Kasem; Eithan Galun; Amnon Peled
Journal:  FASEB J       Date:  2004-06-04       Impact factor: 5.191

9.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.

Authors:  Jennifer M Burns; Bretton C Summers; Yu Wang; Anita Melikian; Rob Berahovich; Zhenhua Miao; Mark E T Penfold; Mary Jean Sunshine; Dan R Littman; Calvin J Kuo; Kevin Wei; Brian E McMaster; Kim Wright; Maureen C Howard; Thomas J Schall
Journal:  J Exp Med       Date:  2006-08-28       Impact factor: 14.307

10.  An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Authors:  Laura Lasagni; Michela Francalanci; Francesco Annunziato; Elena Lazzeri; Stefano Giannini; Lorenzo Cosmi; Costanza Sagrinati; Benedetta Mazzinghi; Claudio Orlando; Enrico Maggi; Fabio Marra; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more
  27 in total

1.  C-X-C motif receptor 7 in gastrointestinal cancer.

Authors:  Hwan-Jung Yun; Hyewon Ryu; Yoon Seok Choi; Ik-Chan Song; Deog-Yeon Jo; Samyong Kim; Hyo Jin Lee
Journal:  Oncol Lett       Date:  2015-06-22       Impact factor: 2.967

Review 2.  Advances in Research on the Effects and Mechanisms of Chemokines and Their Receptors in Cancer.

Authors:  Jing Xu; Jing-Quan Li; Qi-Lei Chen; Elena A Shestakova; Vsevolod A Misyurin; Vadim S Pokrovsky; Elena M Tchevkina; Hu-Biao Chen; Hang Song; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

3.  A chemokine/chemokine receptor signature potentially predicts clinical outcome in colorectal cancer patients.

Authors:  Andrew Mitchell; Sarrah L Hasanali; Daley S Morera; Rohitha Baskar; Xin Wang; Rahil Khan; Asif Talukder; Charles S Li; Meenakkshy Manoharan; Andre R Jordan; Jiaojiao Wang; Roni J Bollag; Nagendra Singh; Daniel Albo; Santu Ghosh; Vinata B Lokeshwar
Journal:  Cancer Biomark       Date:  2019       Impact factor: 4.388

Review 4.  Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review.

Authors:  Qun Chen; Wu-Jun Wang; Yun-Xuan Jia; Hao Yuan; Peng-Fei Wu; Wan-Li Ge; Ling-Dong Meng; Xu-Min Huang; Peng Shen; Tao-Yue Yang; Yi Miao; Jing-Jing Zhang; Kui-Rong Jiang
Journal:  Cell Biosci       Date:  2021-05-13       Impact factor: 7.133

5.  The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.

Authors:  Juyong Liang; Zhijian Jin; Jie Kuang; Haoran Feng; Qiwu Zhao; Zheyu Yang; Ling Zhan; Baiyong Shen; Jiqi Yan; Wei Cai; Xi Cheng; Weihua Qiu
Journal:  Br J Cancer       Date:  2021-06-04       Impact factor: 9.075

6.  A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers.

Authors:  Sadia Mahboob; Seong Beom Ahn; Harish R Cheruku; David Cantor; Emma Rennel; Simon Fredriksson; Gabriella Edfeldt; Edmond J Breen; Alamgir Khan; Abidali Mohamedali; Md Golam Muktadir; Shoba Ranganathan; Sock-Hwee Tan; Edouard Nice; Mark S Baker
Journal:  Clin Proteomics       Date:  2015-04-08       Impact factor: 3.988

7.  Pien Tze Huang Inhibits Hypoxia-Induced Angiogenesis via HIF-1 α /VEGF-A Pathway in Colorectal Cancer.

Authors:  Hongwei Chen; Jianyu Feng; Yuchen Zhang; Aling Shen; Youqin Chen; Jiumao Lin; Wei Lin; Thomas J Sferra; Jun Peng
Journal:  Evid Based Complement Alternat Med       Date:  2015-01-14       Impact factor: 2.629

Review 8.  Diversity and Inter-Connections in the CXCR4 Chemokine Receptor/Ligand Family: Molecular Perspectives.

Authors:  Lukas Pawig; Christina Klasen; Christian Weber; Jürgen Bernhagen; Heidi Noels
Journal:  Front Immunol       Date:  2015-08-21       Impact factor: 7.561

9.  A novel variant on chromosome 6p21.1 is associated with the risk of developing colorectal cancer: a two-stage case-control study in Han Chinese.

Authors:  Chunxiao Xu; Dan Zhou; Feixia Pan; Yi Liu; Dandan Zhang; Aifen Lin; Xiaoping Miao; Yaqin Ni; Duo Lv; Shuai Zhang; Xiaobo Li; Yimin Zhu; Maode Lai
Journal:  BMC Cancer       Date:  2016-10-18       Impact factor: 4.430

Review 10.  G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts.

Authors:  Ernestina M De Francesco; Federica Sotgia; Robert B Clarke; Michael P Lisanti; Marcello Maggiolini
Journal:  Int J Mol Sci       Date:  2017-12-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.